Morphine Patch: Dosage Forms for Strong Opioids

The term morphine patch is commonly used in everyday language to refer to transdermal pain patches containing strong opioids. However, pharmacologically this term is misleading because morphine itself is not available as a patch. The transdermal pain patches approved in Germany contain other opioids, particularly fentanyl or buprenorphine. These substances are suitable for transdermal absorption due to their chemical properties (lipophilicity, small molecular size), whereas morphine itself is not sufficiently absorbed through the skin.

Pain patches play an important role in the treatment of chronic pain, such as cancer pain or severe chronic non-cancer pain. The advantages of patches include continuous drug release over several days, avoidance of the first pass effect, and simple administration in patients with swallowing disorders. Use requires careful indication assessment, patient and caregiver education, and medical supervision due to the potential for dependence and relevant safety concerns.

Definition

When patients or relatives ask for a morphine patch, they usually mean a pain patch containing a strong opioid. In medical prescriptions and pharmacies, the active ingredients are named specifically: fentanyl patch or buprenorphine patch. Both belong to WHO level III of pain management like oral or parenteral morphine, but each with its own pharmacological properties.

Morphine itself is available in oral form (immediate or sustained-release tablets, drops), in injectable form, as a suppository, and as a solution for intrathecal administration. For more information about morphine, please see our Morphine Pillar Page.

Active Ingredients in Pain Patches

Fentanyl Patches are the most widely used form of transdermal opioid therapy in Germany. Available strengths: 12, 25, 50, 75 and 100 micrograms per hour. Application duration 72 hours, then change to a different skin site. Fentanyl is approximately 80 to 100 times more potent analgesically than morphine.

Buprenorphine Patches are an alternative for patients with impaired renal function or milder chronic pain. Available strengths: 5, 10 and 20 micrograms per hour (application duration 7 days) as well as 35, 52.5 and 70 micrograms per hour (application duration 96 hours). Buprenorphine is a partial agonist at the mu opioid receptor and has a ceiling effect for respiratory depression, which improves safety.

Detailed information on both substances can be found on our pillar pages on Fentanyl and Buprenorphine.

Indications

• Cancer Pain WHO level III, when oral opioids are not possible or unsuitable (swallowing disorders, nausea, vomiting, gastrointestinal motility disorder)
• Chronic Non-Cancer Pain after failure of other therapies, very strict indication assessment according to S3 guideline LONTS
• Palliative Situation with high need for continuous opioid effect and reduced oral uptake capacity
• Stable Pain Pattern: patches are not suitable for acute or fluctuating pain because dose adjustment has delayed effect

Patches are unsuitable for acute pain, postoperative pain, and for patients without opioid experience with high potencies (risk of respiratory depression).

Dosage and Administration

Fentanyl Patch: Begin with dose conversion from equivalent oral daily morphine dose. Example: 60 mg oral morphine per day corresponds to a fentanyl patch 25 micrograms per hour. Application 72 hours, then change to a different skin site.

Buprenorphine Patch: Begin with low dose, increase according to effect. Change depending on patch after 96 hours or 7 days.

Application: on dry, intact, hairless skin (chest, upper arm, back, thigh). Clean thoroughly without soap before application, dry well, do not apply cream. Press patch firmly with hand for at least 30 seconds.

Patch Change: always at a different skin site, old site may be reused only after at least 7 days. Fold old patch together (adhesive side inward) and dispose of safely.

Breakthrough Medication: for breakthrough pain, unretarded opioid orally, sublingually or buccally as prescribed by physician.

Renal Impairment: Fentanyl is safer than morphine in renal impairment. Buprenorphine is considered well tolerated in impaired renal function. Hepatic Impairment: caution and dose reduction in severe impairment.

Important: fever can significantly increase absorption. Avoid external heat sources (heating blankets, sunbeds, sauna, hot baths) on the patch area to prevent overdoses with respiratory depression.

Side Effects

Very Common: Nausea (especially at start of therapy), constipation, fatigue, sweating, dizziness, headache, local skin reactions under the patch.

Common: Vomiting, dry mouth, loss of appetite, sleep disturbance, confusion, mood changes, pruritus, erythema.

Occasional to Rare: Hallucinations, respiratory depression (especially with overdose or heat exposure), bradycardia, hypotension, seizures, urinary retention, severe allergic skin reactions.

With Long-term Use: Physical and psychological dependence, tolerance development, hormonal changes (hypogonadism), immunosuppression, hyperalgesia. Upon discontinuation, withdrawal symptoms such as restlessness, sweating, tachycardia, nausea, diarrhea.

Emergency: if signs of respiratory depression occur (drowsiness, slow breathing, cyanosis), immediately call emergency number 112, remove patch, prepare naloxone as antidote. With buprenorphine, naloxone is less effective, higher doses required.

Drug Interactions

• Other Central Depressants (benzodiazepines, Z substances, alcohol, other opioids, antipsychotics): potentially fatal respiratory depression. Combination with benzodiazepines only with strict indication.
• CYP3A4 Inhibitors (ritonavir, ketoconazole, erythromycin, grapefruit juice): increased fentanyl levels, risk of respiratory depression.
• CYP3A4 Inducers (rifampicin, carbamazepine, St. John's Wort): reduced effect, breakthrough pain.
• MAO Inhibitors: caution, serotonin syndrome or hyperadrenergic reaction possible.
• Naloxone: antidote, higher doses needed with buprenorphine.

Special Precautions

Pregnancy: only with strict indication because opioids depress the newborn and can trigger withdrawal symptoms in the child after birth. Breast-feeding: passage into breast milk. Breast-feeding during opioid therapy is possible, but only under observation and medical guidance.

Children: Patch therapy only in specialized pediatric pain centers or palliative settings.

Safety for Family Members: used patches still contain significant amounts of active ingredient. Safe sealing and disposal are important because children or animals can be fatally poisoned.

Before Use: Comprehensive counseling, addiction history, comorbidities, concomitant medication. When initiating patch therapy, detailed training on administration.

During Therapy: Regular monitoring of pain intensity, side effects, cognitive function, hormonal parameters with long-term therapy. Regular assessment of therapy goals and re-evaluation.

Lifestyle: no alcohol, no external heat sources on the patch area, adequate fluid intake, laxatives if necessary for constipation. Do not stop abruptly.

Driving Ability: Opioids impair reaction capacity. With stable therapy and if physician assesses fitness, driving may be allowed after individual evaluation, but not during initiation phase and with dose changes.

You Might Also Be Interested In

• Morphine, gold standard of strong opioids orally and parenterally
• Fentanyl, highly potent opioid in patches and anesthesia
• Buprenorphine, opioid partial agonist as patch
• Oxycodone, strong opioid orally sustained-release
• Naloxone, opioid antagonist as antidote

Frequently Asked Questions

Sources

• Gelbe Liste, Fentanyl Active Ingredient Profile
• Gelbe Liste, Buprenorphine Active Ingredient Profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, S3 Guideline Long-term Use of Opioids in Non-Cancer Pain (LONTS)
• German Society for Palliative Medicine